Skp2: a dream target in the coming age of cancer therapy

  • Cell Cycle. 2014;13(5):679-80. doi: 10.4161/cc.27853.
Chia-Hsin Chan  1 ,  John Kenneth Morrow  2 ,  Shuxing Zhang  2 ,  Hui-Kuan Lin  3
Affiliations
  • 1. Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
  • 2. Department of Experimental Therapeutics; The University of Texas MD Anderson Cancer Center; Houston, TX USA; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA.
  • 3. Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA; Graduate Institute of Basic Medical Science; China Medical University; Taichung, Taiwan; Department of Biotechnology; Asia University; Taichung, Taiwan.
PMID: 24526126 DOI: 10.4161/cc.27853
Keywords
Skp2 inhibitor; cancer stem cells; cancer therapy; cell cycle arrest; glycolysis; in silico modeling; senescence.
Products